Investment analysts at Piper Jaffray Cos. began coverage on shares of Xencor Inc. (NASDAQ:XNCR) in a report released on Tuesday. The brokerage set an “overweight” rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on XNCR. Canaccord Genuity set a $27.00 price target on shares of Xencor and gave the stock a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Wednesday, August 31st. Wedbush reiterated an “outperform” rating and issued a $27.00 price target on shares of Xencor in a research report on Monday, September 12th. Finally, Leerink Swann restated an “outperform” rating and set a $18.00 target price on shares of Xencor in a research report on Wednesday, June 29th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Xencor has a consensus rating of “Buy” and a consensus target price of $23.50.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Xencor (NASDAQ:XNCR) opened at 24.58 on Tuesday. Xencor has a 12 month low of $9.89 and a 12 month high of $26.50. The stock has a market cap of $1.01 billion, a PE ratio of 26.12 and a beta of 2.10. The company has a 50-day moving average of $22.77 and a 200-day moving average of $17.17.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $1.31. The business earned $66 million during the quarter, compared to analyst estimates of $7.43 million. Xencor had a net margin of 39.07% and a return on equity of 22.53%. On average, equities analysts forecast that Xencor will post $0.72 EPS for the current fiscal year.

In related news, insider Edgardo Baracchini, Jr. sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $25.35, for a total transaction of $253,500.00. Following the sale, the insider now owns 10,000 shares of the company’s stock, valued at $253,500. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III sold 30,500 shares of the company’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $21.87, for a total transaction of $667,035.00. Following the sale, the insider now directly owns 7,500 shares in the company, valued at approximately $164,025. The disclosure for this sale can be found here. Corporate insiders own 4.03% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC increased its stake in Xencor by 8.5% in the second quarter. Acrospire Investment Management LLC now owns 6,347 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 495 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in Xencor by 5.0% in the first quarter. UBS Asset Management Americas Inc. now owns 14,800 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 700 shares during the last quarter. BlackRock Inc. increased its stake in Xencor by 363.5% in the second quarter. BlackRock Inc. now owns 11,350 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 8,901 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Xencor by 5.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 21,213 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 1,026 shares during the last quarter. Finally, American International Group Inc. increased its stake in Xencor by 11.1% in the second quarter. American International Group Inc. now owns 18,513 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 1,856 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

5 Day Chart for NASDAQ:XNCR

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.